FDA
approval
· 2026-02-17
FDA Approved: AMBRISENTAN — Supplemental Application (Actavis Pharma, Inc.)
Summary
The FDA approved a supplemental application for ambrisentan (Actavis Pharma, Inc.), a drug used to treat pulmonary arterial hypertension. This action expands/re…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for AMBRISENTAN (AMBRISENTAN)